Infectious Disease In-Vitro Diagnostics Market

Infectious Disease In-Vitro Diagnostics Market by Products (Instruments [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others], Reagents [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE ,Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others], and Services [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB , and Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others]), Applications (MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others), Technology (Immunoassay, Mol

  • Report ID: HC-1634
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 210
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global infectious disease in-vitro diagnostics market size was valued at USD 55.91 billion in 2020 and is expanding at a CAGR of 3.7% during the forecast period, 2021–2028. The launch of high-quality and inexpensive medical explications for lab automation along with the wide prevalence of infectious diseases globally are notable factors driving the market growth.

Infectious Disease In-Vitro Diagnostics Market Key Takeaways

An infectious disease in-vitro diagnostics is primarily designed to detect the main infectious agent in a patient’s body and allow medical practitioners to obtain the right treatment to the patient. The diagnostics involves a range of tests and can help to identify the vectors that cause infectious diseases of patients. For instance, the tests also offer crucial information to prevent many potential epidemics such as bacterial infection and help curb the disease spread. Rapid technology advancements facilitate a range of equipment and system that offer high convenience for patients’ self-treatment as it provides improved diagnostic kits to be used for home settings. The introduction of point of care system and expansion of technology as molecular diagnostics to ensure effective and convenient testing facilities attract the attention of patients for diagnostics.

The outbreak of COVID-19 pandemic has boosted the overall scope for the market expansion and several pharmaceutical companies have started developing several diagnostic kits to detect the virus. Several research and clinical laboratory tests are extensively conducted with massive support from governments across the globe to stop this infectious virus. In March 2020, the COVID-19 test performed by Abbott got received the attention from the government agencies and was granted for urgent use authorization. In July 2020, the National Institutes of Health (NIH) had invested USD 248.7 million to increase the production of diagnostic test under Rapid Acceleration of Diagnostics initiative to help early detection of the coronavirus and control the spread especially in the US. Early, the tests are widely applied to the study and research to AIDS and for the detection of the HIV. According to World Health Organization (WHO), more than 37.9 million people were affected by HIV globally and about 1.7 million new cases of HIV were reported in 2018.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing cases of infection diseases among a large number of the aging population worldwide is expected to boost the market growth during the forecast period.
  • Growing consumer awareness and rising number of health-conscious people are major drivers that help to rise in the adoption of early diagnostic tests. These factors are projected to fuel the market expansion.
  • Advancement in point of care system and availability of advanced but user-friendly diagnostic equipment for the use of home setting environment further push the market growth.
  • Less number of skilled lab technicians handling the testing procedures and certain issues regarding the accuracy of test results are major challenges that can hinder the market growth.
  • External funding for R&D programs and gradual development of innovative diagnostic technology such as immunoassay and microbiology are expected to offer lucrative opportunities for the market.

Scope of the Report

The report on the global infectious disease in-vitro diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Infectious Disease In-Vitro Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Instruments [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others], Reagents [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE ,Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others], and Services [MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others]), Applications (MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB & Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Others), Technology (Immunoassay, Molecular Diagnostics, Microbiology, and Others), and End-users (Point of Care, Central Laboratories, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

BD; bioMérieux SA; Abbott; Quidel Corporation; OraSure Technologies, Inc.; Hologic, Inc. (Gen Probe); Danaher; QIAGEN; F. Hoffmann-La Roch, Ltd.; Siemens Healthineers AG; and Bio-Rad Laboratories, Inc.

Market Segment Insights

Instruments segment is expected to grow at a rapid pace

Based on products, the global infectious disease in-vitro diagnostics market is divided into instruments, reagents, and services. The instruments segment is further segregated into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The reagents segment is also further classified into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The services segment is further partitioned into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The instruments segment held a key share of the market in 2020 and is expected to grow at a rapid pace due to rising demand for diagnostic equipment for testing for various disease treatment applications. However, the reagents segment is anticipated to constitute a large market share during the forecast period owing to the growing use of reagents for various diagnostic development from medical devices manufacturers.

Infectious Disease In-Vitro Diagnostics Market By Products

COVID-19 segment is projected to expand at a considerable CAGR

On the basis of applications, the market is divided into MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB & drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, hepatitis C, hepatitis B, COVID-19, and others. The streptococcus segment is projected to account for a key share of the market. On the other hand, the COVID-19 segment is anticipated to expand at a considerable CAGR during the forecast period due to increasing technology advancements to enable automated and high-throughput testing for the virus. Extensive research conducted by various institutes in collaboration with pharmaceutical companies to produce a massive quantity of diagnostic kits to meet the global needs, present a key aspect for the segment growth.

Immunoassay segment is expected to expand at a robust growth rate

Based on technology, the global infectious disease in-vitro diagnostics market is divided into immunoassay, molecular diagnostics, microbiology, and others. The immunoassay segment is expected to expand at a robust growth rate in the coming years owing to the need for early treatment of patients and increasing demand for immunoassay methods for the same purpose. However, the molecular diagnostics segment is anticipated to expand at a rapid CAGR during the forecast period due to large funding for molecular diagnostic research.

Infectious Disease In-Vitro Diagnostics Market By Technology

Central laboratories segment is expected to register a high CAGR

On the basis of end users, the market is segmented into point of care, central laboratories, and others. The central laboratories segment is expected to register a high CAGR during the forecast period due to the rapid expansion of clinical laboratory facilities across the globe due to rising demand for numerous testing process. However, the point of care segment is projected to register healthy growth rate in the coming years owing to wide preference for self-treatment from patients and rising inclination for home setting screening process. Moreover, the presence of these laboratories in emerging and underdeveloped markets is expected to contribute in the development of new solutions to offer prompt PoC results. This is anticipated to further boost the growth of the segment.

North America is anticipated to constitute a key market share

In terms of regions, the global infectious disease in-vitro diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounted for a key share of the market, representing more than 35.7% of the global revenue share in 2020 and is expected to hold a major market share during the forecast period. The regional market growth is attributed to rising cases of infectious diseases and wide prevalence of COVID-19 cases in the region especially in the US. Since the outbreak of the COVID-19 pandemic, the US has been facing the largest COVID cases and highest number of deaths till the end of mid-2021. Moreover, growing encouragement from governments for the expansion of R&D activities and establishment of advanced diagnostic equipment are boosting the regional market growth.

On the other hand, the market of Asia Pacific is anticipated to expand at a robust CAGR during the forecast period due to the growing number of COVID-19 cases due to the advent of second wave in large economies especially in India. Several research organizations in China have been keenly experimenting numerous clinical tests to improve and expand the existing testing technology to fight against infectious diseases, COVID-19 pandemic in particular.

Infectious Disease In-Vitro Diagnostics Market By Regions

Segments

Segments Covered in the Report
The global infectious disease in-vitro diagnostics market has been segmented on the basis of

Products
  • Instruments
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
  • Reagents
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
  • Services
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
Technology
  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others
Applications
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB & Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others
End-users
  • Point of Care
  • Central Laboratories
  • Others
Regions                  
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • BD
  • bioMérieux SA
  • Abbott
  • Quidel Corporation
  • OraSure Technologies, Inc.
  • Hologic, Inc. (Gen Probe)
  • Danaher
  • QIAGEN
  • F. Hoffmann-La Roche, Ltd.
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.

Competitive Landscape

Key players competing in the global infectious disease in-vitro diagnostics market include BD; bioMérieux SA; Abbott; Quidel Corporation; OraSure Technologies, Inc.; Hologic, Inc. (Gen Probe); Danaher; QIAGEN; F. Hoffmann-La Roch, Ltd.; Siemens Healthineers AG; and Bio-Rad Laboratories, Inc. Some of these key players are widely engaged in various market strategies such as mergers, acquisitions, product tests and development, launching new technology, and capcity expansion. Abbott introduced its technology with CE Mark for DETERMINE HBSAG 2 test for observation and treatment of hepatitis B surface antigen in February 2019.

Infectious Disease In-Vitro Diagnostics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Infectious Disease In-Vitro Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Infectious Disease In-Vitro Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Infectious Disease In-Vitro Diagnostics Market - Supply Chain
  4.5. Global Infectious Disease In-Vitro Diagnostics Market Forecast
     4.5.1. Infectious Disease In-Vitro Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Infectious Disease In-Vitro Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Infectious Disease In-Vitro Diagnostics Market Absolute $ Opportunity
5. Global Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     5.3.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     6.3.1. Point of Care Central Laboratories Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
8. North America Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     8.4.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     8.7.1. Point of Care Central Laboratories Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
9. Latin America Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     9.4.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     9.7.1. Point of Care Central Laboratories Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
10. Europe Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     10.4.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     10.7.1. Point of Care Central Laboratories Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
11. Asia Pacific Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     11.4.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     11.7.1. Point of Care Central Laboratories Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
12. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by Applications
     12.4.1. MRSA Streptococcus Clostridium Difficile VRE CRE  
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Size and Volume Forecast by End Users
     12.7.1. Point of Care Central Laboratories Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Infectious Disease In-Vitro Diagnostics Market: Market Share Analysis
  13.2. Infectious Disease In-Vitro Diagnostics Distributors and Customers
  13.3. Infectious Disease In-Vitro Diagnostics Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. BD bioMérieux SA Abbott Quidel Corporation OraSure Technologies, Inc. Hologic, Inc. (Gen Probe)  
Segments Covered in the Report
The global infectious disease in-vitro diagnostics market has been segmented on the basis of

Products
  • Instruments
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
  • Reagents
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
  • Services
    • MRSA
    • Streptococcus
    • Clostridium Difficile
    • VRE
    • CRE
    • Respiratory Virus
    • Candida
    • TB & Drug-resistant TB
    • Gastro-intestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HPV
    • HIV
    • Hepatitis C
    • Hepatitis B
    • COVID-19
    • Others
Technology
  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others
Applications
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB & Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others
End-users
  • Point of Care
  • Central Laboratories
  • Others
Regions                  
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • BD
  • bioMérieux SA
  • Abbott
  • Quidel Corporation
  • OraSure Technologies, Inc.
  • Hologic, Inc. (Gen Probe)
  • Danaher
  • QIAGEN
  • F. Hoffmann-La Roche, Ltd.
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.

Key players competing in the global infectious disease in-vitro diagnostics market include BD; bioMérieux SA; Abbott; Quidel Corporation; OraSure Technologies, Inc.; Hologic, Inc. (Gen Probe); Danaher; QIAGEN; F. Hoffmann-La Roch, Ltd.; Siemens Healthineers AG; and Bio-Rad Laboratories, Inc. Some of these key players are widely engaged in various market strategies such as mergers, acquisitions, product tests and development, launching new technology, and capcity expansion. Abbott introduced its technology with CE Mark for DETERMINE HBSAG 2 test for observation and treatment of hepatitis B surface antigen in February 2019.

Infectious Disease In-Vitro Diagnostics Market By Key Players

Buy Report